SG11202002565YA - Compositions and methods for ttr gene editing and treating attr amyloidosis - Google Patents
Compositions and methods for ttr gene editing and treating attr amyloidosisInfo
- Publication number
- SG11202002565YA SG11202002565YA SG11202002565YA SG11202002565YA SG11202002565YA SG 11202002565Y A SG11202002565Y A SG 11202002565YA SG 11202002565Y A SG11202002565Y A SG 11202002565YA SG 11202002565Y A SG11202002565Y A SG 11202002565YA SG 11202002565Y A SG11202002565Y A SG 11202002565YA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- gene editing
- ttr gene
- attr amyloidosis
- Prior art date
Links
- 101150091380 TTR gene Proteins 0.000 title 1
- 206010002022 amyloidosis Diseases 0.000 title 1
- 238000010362 genome editing Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Manufacturing & Machinery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762566236P | 2017-09-29 | 2017-09-29 | |
US201862671902P | 2018-05-15 | 2018-05-15 | |
PCT/US2018/053382 WO2019067872A1 (en) | 2017-09-29 | 2018-09-28 | Compositions and methods for ttr gene editing and treating attr amyloidosis |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202002565YA true SG11202002565YA (en) | 2020-04-29 |
Family
ID=63858214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202002565YA SG11202002565YA (en) | 2017-09-29 | 2018-09-28 | Compositions and methods for ttr gene editing and treating attr amyloidosis |
Country Status (15)
Country | Link |
---|---|
US (3) | US20200248180A1 (en) |
EP (1) | EP3688161A1 (en) |
JP (2) | JP2021500864A (en) |
KR (1) | KR20200058509A (en) |
CN (1) | CN111417728A (en) |
AU (1) | AU2018338787A1 (en) |
BR (1) | BR112020005287A2 (en) |
CA (1) | CA3077251A1 (en) |
CO (1) | CO2020005116A2 (en) |
IL (2) | IL311170A (en) |
MX (1) | MX2020003608A (en) |
PH (1) | PH12020550364A1 (en) |
SG (1) | SG11202002565YA (en) |
TW (1) | TW201932479A (en) |
WO (1) | WO2019067872A1 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7139419B2 (en) | 2017-09-29 | 2022-09-20 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Non-Human Animals Containing Humanized TTR Loci and Methods of Use |
WO2020198697A1 (en) * | 2019-03-28 | 2020-10-01 | Intellia Therapeutics, Inc. | Compositions and methods comprising a ttr guide rna and a polynucleotide encoding an rna-guided dna binding agent |
CA3137761A1 (en) * | 2019-06-04 | 2020-12-10 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use |
CN115176001A (en) * | 2019-12-11 | 2022-10-11 | 因特利亚治疗公司 | Modified guide RNAs for gene editing |
WO2022094152A1 (en) * | 2020-10-28 | 2022-05-05 | Neotope Neuroscience Limited | Anti-transthyretin antibodies and methods of use thereof |
IL303506A (en) | 2020-12-11 | 2023-08-01 | Intellia Therapeutics Inc | Polynucleotides, compositions, and methods for genome editing involving deamination |
CN112795595A (en) * | 2020-12-24 | 2021-05-14 | 中山大学 | Gene therapy system for hereditary transthyretin amyloidosis |
AU2022296523A1 (en) | 2021-06-22 | 2023-12-21 | Intellia Therapeutics, Inc. | Methods for in vivo editing of a liver gene |
WO2023028469A2 (en) * | 2021-08-23 | 2023-03-02 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted integration at beta-globin locus in human hematopoietic stem and progenitor cells |
AU2022345881A1 (en) | 2021-09-20 | 2024-03-21 | Alnylam Pharmaceuticals, Inc. | Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof |
CN116064598B (en) * | 2021-10-08 | 2024-03-12 | 苏州艾博生物科技有限公司 | Nucleic acid vaccine for coronavirus |
WO2023185697A2 (en) * | 2022-03-29 | 2023-10-05 | Accuredit Therapeutics (Suzhou) Co., Ltd. | Compositions and methods for treatment of transthyretin amyloidosis |
WO2024003810A1 (en) * | 2022-06-30 | 2024-01-04 | Geneditbio Limited | Guide rna with chemical modifications |
WO2024003805A1 (en) * | 2022-06-30 | 2024-01-04 | Geneditbio Limited | Methods and compositions for ttr gene editing and therapy using crispr system |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
WO1993013121A1 (en) | 1991-12-24 | 1993-07-08 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
JPH10500310A (en) | 1994-05-19 | 1998-01-13 | ダコ アクティーゼルスカブ | PNA probes for the detection of Neisseria gonorrhoeae and Chlamydia trachomatis |
US6974667B2 (en) | 2000-06-14 | 2005-12-13 | Gene Logic, Inc. | Gene expression profiles in liver cancer |
US7244764B2 (en) * | 2003-06-23 | 2007-07-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
WO2006007712A1 (en) | 2004-07-19 | 2006-01-26 | Protiva Biotherapeutics, Inc. | Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents |
US20110237646A1 (en) | 2008-08-07 | 2011-09-29 | Isis Pharmaceuticals, Inc. | Modulation of transthyretin expression for the treatment of cns related disorders |
ES2656516T3 (en) | 2008-10-20 | 2018-02-27 | Alnylam Pharmaceuticals, Inc. | Compositions and methods to inhibit the expression of transthyretin |
US9101643B2 (en) | 2009-11-03 | 2015-08-11 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR) |
NZ603339A (en) | 2010-04-29 | 2015-01-30 | Isis Pharmaceuticals Inc | Modulation of transthyretin expression |
IN2014CN03463A (en) | 2011-11-18 | 2015-10-09 | Alnylam Pharmaceuticals Inc | |
US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
EP2931897B1 (en) * | 2012-12-12 | 2017-11-01 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
US8993233B2 (en) | 2012-12-12 | 2015-03-31 | The Broad Institute Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
KR20150095861A (en) | 2012-12-17 | 2015-08-21 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Rna-guided human genome engineering |
ES2887254T3 (en) | 2013-03-08 | 2021-12-22 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
SG11201508028QA (en) | 2013-04-16 | 2015-10-29 | Regeneron Pharma | Targeted modification of rat genome |
NZ631552A (en) | 2013-05-01 | 2017-02-24 | Ionis Pharmaceuticals Inc | Compositions and methods for modulating hbv expression |
BR112015031611A2 (en) * | 2013-06-17 | 2017-12-12 | Massachusetts Inst Technology | application, manipulation and optimization of systems, methods and compositions for targeting and modeling post-mitotic cell diseases and disorders |
US20150166982A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting pi3k point mutations |
ES2774968T3 (en) | 2013-12-19 | 2020-07-23 | Novartis Ag | Lipids and lipid compositions for the administration of active agents |
US20170191123A1 (en) * | 2014-05-28 | 2017-07-06 | Toolgen Incorporated | Method for Sensitive Detection of Target DNA Using Target-Specific Nuclease |
RU2771532C2 (en) * | 2014-06-26 | 2022-05-05 | Регенерон Фармасьютикалз, Инк. | Methods and compositions for targeted genetic modifications and their application methods |
ES2949172T3 (en) | 2014-07-16 | 2023-09-26 | Novartis Ag | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
CN107532161A (en) | 2015-03-03 | 2018-01-02 | 通用医疗公司 | The specific engineering CRISPR Cas9 nucleases of PAM with change |
JP6799058B2 (en) * | 2015-09-21 | 2020-12-09 | アークトゥラス・セラピューティクス・インコーポレイテッドArcturus Therapeutics,Inc. | Allele selective gene editing and its use |
FI3954225T3 (en) | 2015-09-21 | 2023-12-28 | Trilink Biotechnologies Llc | Initiating capped oligonucleotide primers for synthesizing 5'-capped rnas |
MX2018005332A (en) * | 2015-11-06 | 2018-11-09 | Crispr Therapeutics Ag | Materials and methods for treatment of glycogen storage disease type 1a. |
US11851653B2 (en) | 2015-12-01 | 2023-12-26 | Crispr Therapeutics Ag | Materials and methods for treatment of alpha-1 antitrypsin deficiency |
EP3429632B1 (en) | 2016-03-16 | 2023-01-04 | CRISPR Therapeutics AG | Materials and methods for treatment of hereditary haemochromatosis |
WO2017173054A1 (en) * | 2016-03-30 | 2017-10-05 | Intellia Therapeutics, Inc. | Lipid nanoparticle formulations for crispr/cas components |
WO2018007871A1 (en) * | 2016-07-08 | 2018-01-11 | Crispr Therapeutics Ag | Materials and methods for treatment of transthyretin amyloidosis |
TWI835719B (en) | 2016-12-08 | 2024-03-21 | 美商英特利亞醫療公司 | Modified guide rnas |
-
2018
- 2018-09-28 SG SG11202002565YA patent/SG11202002565YA/en unknown
- 2018-09-28 TW TW107134336A patent/TW201932479A/en unknown
- 2018-09-28 CN CN201880076628.6A patent/CN111417728A/en active Pending
- 2018-09-28 AU AU2018338787A patent/AU2018338787A1/en active Pending
- 2018-09-28 CA CA3077251A patent/CA3077251A1/en active Pending
- 2018-09-28 IL IL311170A patent/IL311170A/en unknown
- 2018-09-28 MX MX2020003608A patent/MX2020003608A/en unknown
- 2018-09-28 WO PCT/US2018/053382 patent/WO2019067872A1/en active Application Filing
- 2018-09-28 KR KR1020207012163A patent/KR20200058509A/en not_active Application Discontinuation
- 2018-09-28 EP EP18786638.9A patent/EP3688161A1/en active Pending
- 2018-09-28 JP JP2020517500A patent/JP2021500864A/en active Pending
- 2018-09-28 BR BR112020005287-6A patent/BR112020005287A2/en unknown
-
2020
- 2020-03-15 IL IL273317A patent/IL273317A/en unknown
- 2020-03-24 US US16/828,573 patent/US20200248180A1/en active Pending
- 2020-03-27 PH PH12020550364A patent/PH12020550364A1/en unknown
- 2020-04-24 CO CONC2020/0005116A patent/CO2020005116A2/en unknown
-
2022
- 2022-12-06 JP JP2022194564A patent/JP2023029966A/en active Pending
- 2022-12-09 US US18/063,972 patent/US11965165B2/en active Active
- 2022-12-09 US US18/064,086 patent/US11795460B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA3077251A1 (en) | 2019-04-04 |
IL311170A (en) | 2024-04-01 |
PH12020550364A1 (en) | 2021-02-15 |
BR112020005287A2 (en) | 2020-09-24 |
KR20200058509A (en) | 2020-05-27 |
US20230257747A1 (en) | 2023-08-17 |
JP2021500864A (en) | 2021-01-14 |
MX2020003608A (en) | 2020-09-25 |
CN111417728A (en) | 2020-07-14 |
IL273317A (en) | 2020-04-30 |
WO2019067872A1 (en) | 2019-04-04 |
US11965165B2 (en) | 2024-04-23 |
EP3688161A1 (en) | 2020-08-05 |
TW201932479A (en) | 2019-08-16 |
JP2023029966A (en) | 2023-03-07 |
US11795460B2 (en) | 2023-10-24 |
US20200248180A1 (en) | 2020-08-06 |
AU2018338787A1 (en) | 2020-04-16 |
CO2020005116A2 (en) | 2020-05-15 |
US20230118592A1 (en) | 2023-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL273317A (en) | Compositions and methods for ttr gene editing and treating attr amyloidosis | |
ZA202006627B (en) | Methods and compositions for treating cancer | |
IL273817A (en) | Compositions and methods for editing rna | |
IL267247B (en) | Compositions and methods for treating cancer | |
HK1256817A1 (en) | Compositions and methods for genome editing | |
IL269150A (en) | Compositions and methods for treating cancer | |
IL266053A (en) | Compositions and methods for treating ezh2-mediated cancer | |
GB2587970B (en) | Compositions and methods for gene editing | |
IL271232A (en) | Compositions and methods for genome editing | |
IL269620A (en) | Compositions and methods for treating phenylketonuria | |
IL304820A (en) | Compositions and methods for treating cancer | |
PT3377516T (en) | Methods and compositions for treating cancer | |
IL273378A (en) | Compositions and methods for treating transthyretin (ttr) mediated amyloidosis | |
IL269157A (en) | Compositions and methods for treating cancer | |
IL256523A (en) | Compositions and methods for treating cancer | |
SG11202012435UA (en) | Compositions and methods for treating cancer | |
IL264167A (en) | Compositions and methods for treating frontotemporal dementia | |
IL285886A (en) | Compositions and methods for treating laminopathies | |
RS63446B1 (en) | Compositions for treating amyloidosis | |
SG10202013112YA (en) | Zinc-gamma-pga compositions and methods for treating cancer | |
EP3723733A4 (en) | Methods and compositions for treating cancer using exosomes-associated gene editing | |
HK1255835A1 (en) | Therapeutic compositions and methods for treating hepatitis b | |
IL255638A (en) | Compositions and methods for treating cancer | |
IL285796A (en) | Methods and compositions for treating | |
IL272782A (en) | Compositions and methods for treating cancer |